News

Tomato genome decoded
Enlarge image

ResearchUKSpainBelgiumItaly

Tomato genome decoded

31.05.2012 - Researchers have decoded the tomato genome, laying the foundation for smart breeding of other species of the solanaceae family.

Ghent, Rome, Harpenden, Washington – A consortium of 300 researchers from 14 countries has decoded 80% of the tomato genome, and 90% of its 35,000 protein-coding genes. The leaders of the UK arm of the Tomato Genome Consortium (TGC), Graham Seymour at the University of Nottingham and Gerard Bishop, formerly of Imperial College London, stressed the sequence will make precision breeding possible not just in tomatoes, but also in other crop species from the Solanaceae or nightshade family, such as aubergines and peppers.

They said it could help to develop tomato varieties that can survive pests, pathogens and even climate change, as well as high-yield crops that still have a good flavour. “It’s really all about making a better tomato,” commented Allen Van Deynze, a molecular geneticist at the Seed Biotechnology Center at the University of California, Davis. “This work enables a lot of things we just couldn’t do before.”

 The researchers compared the sequences a domesticated tomato variety used to produce the famous ketchup („Heinz1706“) and its closest wild relative, /Solanum pimpinellifolium/ and its functional consequences.  "For any characteristic of the tomato, whether it's taste, natural pest resistance or nutritional content, we've captured virtually all those genes," said James Giovannoni from the Boyce Thompson Institute for Plant Research at Cornell University, who was part of the U.S. tomato sequencing team.  The research also offers some insight into how the tomato ripens and how its relatives diversified and adapted to new environments.  Using traditional Sanger sequencing, the TGC started its work in 2003 but the genome sequence still had major holes by 2008. Next generation sequencing helped the consortium to close the gaps and to translate the genetic information into biological functions. Belgian experts from VIB and University Ghent mainly lead the gene prediction that translated the raw genome sequence in biological knowledge.

http://www.european-biotechnology-news.com/news/news/2012-02/tomato-genome-decoded.html

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%

TOP

  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%

FLOP

  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%

TOP

  • SANTHERA98.00 CHF2412.8%
  • CYTOS1.32 CHF676.5%
  • WILEX5.08 EUR497.6%

FLOP

  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.9%

No liability assumed, Date: 05.05.2015